Andere Sprachen Immix Biopharma, Inc.

Aktien

A3C9EJ

US45258H1068

IMMX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
2.31 ^USD	+6.45%		+10.00%	-66.62%

29.04.	Immix Biopharma erhält Orphan Drug Label in Europa für die Behandlung des Multiplen Myeloms	MT
18.04.	Immix Biopharma, Inc. gibt bekannt, dass die Verabreichung von NXC-201 an Patienten in den Vereinigten Staaten planmäßig verläuft	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	29.04.
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma	29.04.
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	18.04.
Immix Biopharma on Track to Dose NXC-201 Patients in United States	18.04.
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18.04.
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	16.04.
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15.04.
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20.03.
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20.03.
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20.03.
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative	06.03.
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05.03.
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05.03.
Immix Biopharma 12 Month Review Progress Update	21.02.
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08.02.
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08.02.
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07.02.
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07.02.
Immix Biopharma Prices $15 Million Stock Offering	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immix Biopharma, Inc.

Aktien

A3C9EJ

US45258H1068

IMMX

Andere Sprachen

Filter